Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-792-2861
Dr. DiNardo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2009
- University of Michigan Medical SchoolClass of 2006
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2012 - 2027
- AZ State Medical License 2022 - 2026
- GA State Medical License 2022 - 2026
- TN State Medical License 2022 - 2026
- AL State Medical License 2023 - 2025
- LA State Medical License 2022 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Mar 01
- Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Start of enrollment: 2017 Nov 15
- Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Start of enrollment: 2018 Jan 17
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsClinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.Jayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, Guillermo Garcia-Manero, Tapan M Kadia
American Journal of Hematology. 2025-05-01 - Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes.Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Yu-An Kuo
Blood. 2025-04-03 - VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-u...Mahesh Swaminathan, Courtney D DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian
Blood Cancer Journal. 2025-04-02
Journal Articles
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
- Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
- Join now to see all
Abstracts/Posters
- Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic SyndromeCourtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Therapy of Acute Myeloid Leukemia: Adapting to Change61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).2019 ASCO Annual Meeting - 6/1/2019
- Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
- Join now to see all
Press Mentions
- MD Anderson Unveils Key Research Breakthroughs: Highlights from March 12, 2025March 12th, 2025
- MD Anderson Research Highlights for March 12, 2025March 12th, 2025
- Combination Therapy Yields Strong Long-Term Overall Response Rate in Newly Diagnosed Acute Myeloid Leukemia PatientsMarch 6th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: